Patents Assigned to BLUEPRINT MEDICINES
  • CDK2 inhibitors
    Patent number: 11970498
    Abstract: The present disclosure provides a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Grant
    Filed: February 8, 2023
    Date of Patent: April 30, 2024
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Douglas Wilson, Neil Bifulco, Jr., Natasja Brooijmans, Joseph L. Kim, Philip D. Ramsden, Richard Vargas, Steven Mark Wenglowsky
  • INHIBITORS OF PROTEIN KINASE A
    Publication number: 20240132490
    Abstract: Described herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof and solvates of any of the foregoing capable of inhibiting protein kinase A and/or its mutants, pharmaceutical compositions comprising at least one of the compounds, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, processes for making the compounds, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, and methods of using the same.
    Type: Application
    Filed: February 1, 2022
    Publication date: April 25, 2024
    Applicant: Blueprint Medicines Corporation
    Inventors: Neil Bifulco, Joseph L. Kim, Stefanie Sandra Schalm, Kevin J. Wilson, Michael Ross Palmer
  • Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1- f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
    Patent number: 11964980
    Abstract: Crystalline Forms of Compound (I): pharmaceutically acceptable salts thereof and solvates of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions associated with oncogenic KIT and PDGFRA alterations using the same, and methods for making Compound (I) and crystalline forms thereof are also disclosed.
    Type: Grant
    Filed: December 8, 2022
    Date of Patent: April 23, 2024
    Assignee: Blueprint Medicines Corporation
    Inventors: Joshua D. Waetzig, Gordon Wilkie
  • CDK2 inhibitors
    Patent number: 11932648
    Abstract: The present disclosure provides a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Grant
    Filed: June 27, 2022
    Date of Patent: March 19, 2024
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Douglas Wilson, Neil Bifulco, Jr., Natasja Brooijmans, Joseph L. Kim, Emanuele Perola, Philip D. Ramsden, Richard Vargas, Steven Mark Wenglowsky
  • RET inhibitor for use in treating cancer having a RET alteration
    Patent number: 11872192
    Abstract: Disclosed herein are methods for treating a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of 60 mg to 400 mg of the selective RET inhibitor once daily.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: January 16, 2024
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Erica Evans Raab, Beni B. Wolf
  • Compositions useful for treating disorders related to KIT
    Patent number: 11827642
    Abstract: Compounds and compositions useful for treating disorders related to mutant KIT are described herein.
    Type: Grant
    Filed: November 9, 2022
    Date of Patent: November 28, 2023
    Assignee: Blueprint Medicines Corporation
    Inventors: Brian L. Hodous, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Yulian Zhang
  • EGFR inhibitors
    Patent number: 11718602
    Abstract: The present disclosure provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Grant
    Filed: August 8, 2022
    Date of Patent: August 8, 2023
    Assignee: Blueprint Medicines Corporation
    Inventors: Natasja Brooijmans, Jason D. Brubaker, John Emmerson Campbell, Christopher De Savi, Thomas A. Dineen, Meredith Suzanne Eno, Joseph L. Kim, Aysegul Ozen, Emanuele Perola, Brett D. Williams, Douglas Wilson, Kevin J. Wilson
  • Inhibitors of activin receptor-like kinase
    Patent number: 11634422
    Abstract: Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: April 25, 2023
    Assignee: Blueprint Medicines Corporation
    Inventors: Natasja Brooijmans, Jason D. Brubaker, Paul E. Fleming, Brian Lewis Hodous, Joseph L. Kim, Brett D. Williams, Douglas Wilson, Kevin J. Wilson, Mark Cronin
  • MAP4K1 inhibitors
    Patent number: 11534441
    Abstract: One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are selective MAP4K1 inhibitors, which can be used to treat a diseases or disorders in a subject that benefits from control of MAP4K1 activity.
    Type: Grant
    Filed: January 14, 2021
    Date of Patent: December 27, 2022
    Assignee: Blueprint Medicines Corporation
    Inventors: Jason D. Brubaker, Chandrasekhar V. Miduturu, Michael J. Burke, Thomas A. Dineen, Joseph L. Kim, Joshua T. Close, Emanuele Perola
  • PRKC FUSIONS
    Publication number: 20220213553
    Abstract: The invention provides PRKC gene fusions, PRKC fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with PRKC fusions, such as conditions mediated by aberrant PRKC expression or activity, or overexpression of PRKC.
    Type: Application
    Filed: January 21, 2022
    Publication date: July 7, 2022
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: Nicolas STRANSKY, Joseph L. Kim
  • RAF1 FUSIONS
    Publication number: 20220205045
    Abstract: The invention provides to RAF1 gene fusions, RAF1 fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with RAF1 fusions, such as conditions mediated by aberrant RAF1 expression or activity, or overexpression of RAF1.
    Type: Application
    Filed: September 30, 2021
    Publication date: June 30, 2022
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: Nicolas STRANSKY, Joseph L. Kim
  • Inhibitors of RET
    Patent number: 11279688
    Abstract: Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: March 22, 2022
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Jason D. Brubaker, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Lucian V. DiPietro
  • RET inhibitor for use in treating cancer having a RET alteration
    Patent number: 11273160
    Abstract: Disclosed herein are methods for treating a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of 60 mg to 400 mg of the selective RET inhibitor once daily.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: March 15, 2022
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Erica Evans Raab, Beni B. Wolf
  • PRKC fusions
    Patent number: 11261497
    Abstract: The invention provides PRKC gene fusions, PRKC fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with PRKC fusions, such as conditions mediated by aberrant PRKC expression or activity, or overexpression of PRKC.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: March 1, 2022
    Assignee: Blueprint Medicines Corporation
    Inventors: Nicolas Stransky, Joseph L. Kim
  • Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
    Patent number: 11236086
    Abstract: Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: February 1, 2022
    Assignee: Blueprint Medicines Corporation
    Inventors: Jason D. Brubaker, Paul E. Fleming, Joseph L. Kim, Brett Williams, Brian L. Hodous
  • COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT
    Publication number: 20210284645
    Abstract: Compounds and compositions useful for treating disorders related to mutant KIT are described herein.
    Type: Application
    Filed: October 14, 2020
    Publication date: September 16, 2021
    Applicants: Blueprint Medicines Corporation, Blueprint Medicines Corporation
    Inventors: Brian L. Hodous, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Yulian Zhang
  • Compounds and compositions useful for treating disorders related to NTRK
    Patent number: 11059827
    Abstract: This invention relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: July 13, 2021
    Assignee: Blueprint Medicines Corporation
    Inventors: Steven Mark Wenglowsky, Chandrasekhar V. Miduturu, Neil Bifulco, Joseph L. Kim
  • Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
    Patent number: 11040979
    Abstract: Compounds and compositions useful for treating disorders related to KIT and PDGFR are described herein.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: June 22, 2021
    Assignee: Blueprint Medicines Corporation
    Inventors: Brian L. Hodous, Joseph L. Kim, Kevin J. Wilson
  • Inhibitors of the fibroblast growth factor receptor
    Patent number: 10875837
    Abstract: Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: December 29, 2020
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Neil Bifulco, Jr., Lucian V. DiPietro, Brian L. Hodous, Chandrasekhar V. Miduturu
  • PIK3C2G fusions
    Patent number: 10875930
    Abstract: The invention provides to PIK3C2G (phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma) gene fusions and PIK3C2G fusion proteins. The invention further provides methods of diagnosing and treating diseases or disorders associated with PK3C2G fusions, such as conditions mediated by aberrant PIK3C2G expression or activity, or conditions associated with overexpression of PIK.3C2G.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: December 29, 2020
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Nicolas Stransky, Ethan G. Cerami, Joseph L. Kim, Christoph Lengauer